Evidence map›Paper›PMID 28529585›Full record

ArticleOncology letters2017

Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial.

Jie Xiao, Jian Zhou, Min Fu, Li Liang, Qiaoling Deng, Xiaoyun Liu, Fumin Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Advancements inMolecules (Basel, Switzerland) · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Immunohistochemical WWOX Expression and Association with Angiogenesis, p53 Expression, Cell Proliferation and Clinicopathological Parameters in Cervical Cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2018
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jie XiaoDepartment of Gynecology, Xuzhou Maternity and Child Health Care Hospital, Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China.
Jian ZhouDepartment of Gynecology, Xuzhou Maternity and Child Health Care Hospital, Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China.
Min FuCervical Disease Center, Xuzhou Maternity and Child Health Care Hospital, Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China.
Li LiangDepartment of Gynecology, Xuzhou Maternity and Child Health Care Hospital, Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China.
Qiaoling DengDepartment of Gynecology, Xuzhou Maternity and Child Health Care Hospital, Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China.
Xiaoyun LiuCenter Laboratory, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China.
Fumin LiuDepartment of Obstetrics and Gynecology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 22l002, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to evaluate the efficacy and safety of recombinant human adenovirus-p53 (rhAd-p53) combined with neoadjuvant chemotherapy in treatment of locally advanced cervical cancer (LACC). A total of 40 patients with LACC (stage IB2 to IIIA) were randomized into 2 groups (n=20 each): PVB group (cisplatin + vincristine + bleomycin, intravenously) and combined group (rhAd-p53 gene therapy + neoadjuvant chemotherapy). Both groups underwent a course of chemotherapy; the only exception was the injection of the rhAd-p53 solution 1×10

Indexed as

adenovirusescervical cancerchemotherapycombinationgeneshumanp53

Identifiers

PMID28529585
PMCPMC5431581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.